All Stories

Octagon shuts down after R&D challenges put it behind the 8 ball

Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after deprioritizing its lead program and running into unresolved biology questions.

Apr 29, 2025 - 12:47
 0
Octagon shuts down after R&D challenges put it behind the 8 ball
Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after deprioritizing its lead program and running into unresolved biology questions.
Read More

Tags:

Previous Article

Suntory Global Spirits boosts commercial excellence team in APAC

Next Article

STAT+: Novo Nordisk strikes telehealth deals for obesity drug, following Eli Lilly

Related Posts

Mosaic adds to cancer combo pattern by licensing 2 clinical-stage drugs from Astex

Mosaic adds to cancer combo pattern by licensing 2 clin...

Apr 24, 2025  0

Senators call for probe into brain-computer interfaces, neural data collection and security practices

Senators call for probe into brain-computer interfaces,...

Apr 28, 2025  0

Tonix Pharmaceuticals culls cocaine intoxication trial amid enrollment woes

Tonix Pharmaceuticals culls cocaine intoxication trial ...

Apr 28, 2025  0